- Home
- ALZN vs SCNI Comparison
ALZN vs SCNI Comparison
Compare ALZN & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALZN
- SCNI
- Stock Information
- Founded
- ALZN 2016
- SCNI 2003
- Country
- ALZN United States
- SCNI Israel
- Employees
- ALZN N/A
- SCNI N/A
- Industry
- ALZN Medicinal Chemicals and Botanical Products
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALZN Health Care
- SCNI Health Care
- Exchange
- ALZN Nasdaq
- SCNI Nasdaq
- Market Cap
- ALZN 2.3M
- SCNI 2.0M
- IPO Year
- ALZN 2021
- SCNI N/A
- Fundamental
- Price
- ALZN $2.35
- SCNI $1.52
- Analyst Decision
- ALZN Strong Buy
- SCNI
- Analyst Count
- ALZN 1
- SCNI 0
- Target Price
- ALZN $180.00
- SCNI N/A
- AVG Volume (30 Days)
- ALZN 216.5K
- SCNI 3.0M
- Earning Date
- ALZN 09-10-2025
- SCNI 08-19-2025
- Dividend Yield
- ALZN N/A
- SCNI N/A
- EPS Growth
- ALZN N/A
- SCNI N/A
- EPS
- ALZN N/A
- SCNI N/A
- Revenue
- ALZN N/A
- SCNI $658,000.00
- Revenue This Year
- ALZN N/A
- SCNI N/A
- Revenue Next Year
- ALZN N/A
- SCNI N/A
- P/E Ratio
- ALZN N/A
- SCNI N/A
- Revenue Growth
- ALZN N/A
- SCNI N/A
- 52 Week Low
- ALZN $2.06
- SCNI $1.40
- 52 Week High
- ALZN $135.54
- SCNI $6.18
- Technical
- Relative Strength Index (RSI)
- ALZN 35.09
- SCNI 29.96
- Support Level
- ALZN $2.14
- SCNI $1.40
- Resistance Level
- ALZN $2.44
- SCNI $1.64
- Average True Range (ATR)
- ALZN 0.17
- SCNI 0.24
- MACD
- ALZN -0.03
- SCNI -0.03
- Stochastic Oscillator
- ALZN 23.97
- SCNI 5.77
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.